Pritelivir - AiCuris

Drug Profile

Pritelivir - AiCuris

Alternative Names: AIC-316; BAY 57-1293

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Developer AiCuris
  • Class Amides; Antivirals; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action DNA helicase-primase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Herpes simplex virus infections

Highest Development Phases

  • Phase II Herpes labialis; Herpes simplex virus infections; Herpes simplex virus type 2 infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections(In volunteers) in Germany (PO)
  • 13 Oct 2017 AiCuris Anti-infective Cures and TKL Research completes the phase II LipP1 trial for Herpes labialis (In treatment-experienced) in USA (Topical) (NCT02871492)
  • 01 Aug 2017 Pritelivir receives Fast Track designation for Herpes simplex virus infections [PO,Tablet] (Treatment-resistant) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top